Novartis expects biosimilar launches for its Sandoz division to drive “material growth in the back half of 2023, into 2024, and beyond,” with Sandoz’ group turnover for 2021 flat as reported and its core operating profit tumbling by 12% on the same basis.
“Our biosimilars launches continue to be on track,” management told attendees to Novartis’ fourth-quarter and full-year earnings call, as annual turnover from Sandoz’
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?